T2 BIOSYSTEMS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.16 USD | -5.24% |
|
+28.40% | -33.71% |
Presentation Operator MessageOperator (Operator)Good afternoon and welcome to the T2 Biosystem...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
T2 Biosystems, Inc. is an in vitro diagnostics company focused on the detection of sepsis-causing pathogens and antibiotic resistance genes. Its technology enables detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its focus includes three areas: sepsis, bioterrorism, and Lyme disease. The Company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the T2 Magnetic Resonance (T2MR) technology. It also has an active pipeline of products, including the United States T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. T2Dx Instrument is a fully automated instrument that is capable of running a range of diagnostic tests from patient samples.
Calendar
2024-07-30
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
4.39
USD
Average target price
3
USD
Spread / Average Target
-31.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -33.71% | 59.45M | |
| +12.06% | 225B | |
| +12.07% | 186B | |
| +13.88% | 135B | |
| +27.12% | 107B | |
| +0.91% | 63.56B | |
| +6.74% | 51.32B | |
| +13.39% | 51.04B | |
| +8.81% | 43.3B | |
| +4.14% | 36.99B |
- Stock Market
- Equities
- TTOO Stock
- News T2 Biosystems, Inc.
- Transcript : T2 Biosystems, Inc., Q3 2021 Earnings Call, Nov 04, 2021